Redmile Group LLC 13D and 13G filings for Akero Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 4:26 pm Sale | 2023-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Redmile Group LLC | 1,109,476 2.000% | -1,523,436 (-57.86%) | Filing |
| 2023-02-14 4:23 pm Purchase | 2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Redmile Group LLC | 2,632,912 5.600% | 1,030,627 (+64.32%) | Filing |
| 2022-02-14 5:07 pm Sale | 2021-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Redmile Group LLC | 1,602,285 4.600% | -720,272 (-31.01%) | Filing |
| 2021-02-16 4:05 pm Purchase | 2020-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Redmile Group LLC | 2,322,557 6.690% | 2,322,557 (New Position) | Filing |